Fluocinolone acetonide 190 micrograms intravitreal implant (Iluvien®)

Following a resubmission, the SMC has accepted fluocinolone acetonide intravitreal implant (Iluvien®) for restricted use within NHS Scotland for the treatment of vision impairment associated with chronic diabetic macular oedema that has not responded to available therapies.

The use of Iluvien® is restricted to patients in whom the affected eye is pseudophakic (has an artificial lens after cataract surgery). Retreatment is only permitted if the patient had previously responded to treatment with fluocinolone acetonide and subsequently best corrected visual acuity had deteriorated to less than 20/32. 

 

This SMC advice takes account of, and is contingent upon the continuing availability of, a Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.